- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 | 3 | Cision News | ||
| 10.04. | Lytix Biopharma AS: Annual Report for 2024 | 1 | Cision News | ||
| 13.02. | LYTIX BIOPHARMA AS: Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 | 3 | Cision News | ||
| 12.02. | LYTIX BIOPHARMA AS: Lytix Biopharma receives Notice of Allowance for U.S. patent application covering its LTX-315 clinical program | 2 | Cision News | ||
| 07.02. | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q4 2024 Results Presentation | 1 | Cision News | ||
| 22.01. | Lytix Biopharma AS - Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference | 6 | Cision News | ||
| LYTIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 15.01. | Lytix Biopharma AS - New share capital registered | 1 | Cision News | ||
| 07.01. | Lytix Biopharma AS - Cancellation of Subsequent Offering | 3 | Cision News | ||
| 02.01. | Lytix Biopharma AS: Financial calendar | - | Oslo Børs | ||
| 23.12.24 | Lytix Biopharma AS - New share capital registered | 2 | Cision News | ||
| 17.12.24 | Lytix Biopharma AS: Key information relating to potential subsequent offering | 1 | Cision News | ||
| 17.12.24 | Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates | 1 | Cision News | ||
| 17.12.24 | Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed | 1 | Cision News | ||
| 16.12.24 | Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid | 3 | Cision News | ||
| 16.12.24 | Lytix Biopharma AS: Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement | 1 | Oslo Børs | ||
| 21.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion | 4 | Cision News | ||
| 19.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization | 1 | Cision News | ||
| 12.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q3 2024 Results Presentation | 1 | Cision News | ||
| 06.11.24 | Lytix Biopharma AS: First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma | - | Oslo Børs | ||
| 05.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals | 11 | Cision News |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
LYTIX BIOPHARMA AS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,409 Euro und damit +1,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYTIX BIOPHARMA AS finden Sie auf Wallstreet Online.
